TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07293754: An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Sponsor: Repertoire Immune Medicines · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$3,691,380

Rescue Site Savings

+$2,434,740

Unlock Full NCT07293754 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07293754 Rescue Dossier →